PrognomiQ, a healthcare company focused on multi-omics approaches to disease detection, has raised $34 million in Series D funding, led by Seer, Inc., with participation from new and existing investors, including Catalio Capital Management, aMoon, Invus, and Bruker. This brings the company’s total funding to over $135 million and will accelerate the development of its early lung cancer detection test.
Lung cancer remains a leading cause of cancer-related deaths globally, and early detection is critical for improving survival rates. However, current screening methods have limitations. PrognomiQ aims to address this gap with its innovative multi-omics test, which combines data from proteomics, genomics, metabolomics, and other sources to identify potential biomarkers for more accurate and accessible screening.
The company has shown promising results in its research. A recent study involving over 2,500 participants demonstrated 89% sensitivity and specificity in detecting lung cancer, including 80% sensitivity for stage 1 lung cancer. PrognomiQ has also received a Clinical Laboratory Improvement Amendment (CLIA) license to develop its lab-developed test (LDT) and is enrolling participants for a large-scale, 15,000-subject study to support the registration of its in vitro diagnostic (IVD) test.
The new funding will help PrognomiQ advance the commercialization of its LDT, pursue regulatory approval for its IVD test, and further enhance its multi-omics platform for detecting other complex diseases. PrognomiQ's CEO, Philip Ma, expressed gratitude for the continued support from investors and emphasized the potential of its early lung cancer detection technology to improve patient outcomes globally.
Click here to read the original news story.